Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service EP ablation cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 29 | 1,441 | 14% |
| 2020 | 30 | 1,272 | 15% |
| 2021 | 35 |
AF, SVT, and VT catheter ablation. Professional codes (what the surgeon bills): CPT 93656, 93653, 93654; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 40% of the cases CMS names in Maryland; 26 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 50 | 3,380−1.5%/yr | −1.5%/yr | 3.90.7× | 1% | 3,330 in 2030−0.2%/yr |
| LAA occlusion & loop recorders |
EP ablation in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Florida
| 2024 |
| 2,173 |
| 28% |
| 2025 est. | ≈ 2,430 | – |
| 2026 est. | ≈ 2,660 | – |
| 1,677 |
| 19% |
| 2022 | 32 | 1,658 | 22% |
| 2023 | 40 | 2,012 | 25% |
| 2024 | 43 | 2,173 | 28% |
| 2025 from claims | – | 2,429 2,229–2,570 | 29% |
| 2026 forecast | – | 2,655 2,336–3,064 | 29% |
| 2027 forecast | – | 2,867 2,451–3,417 | 29% |
| 2028 forecast | – | 3,096 2,583–3,791 | 30% |
| 2029 forecast | – | 3,343 2,730–4,192 | 31% |
| 2030 forecast | – | 3,609 2,891–4,624 | 31% |
In 2025, 3% inpatient hospital, 97% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +7.5%/yr |
| 4.2 |
| 0% |
| 20,900 in 2030+11%/yr |
| Virginia | 75 | 5,013+9.4%/yr | +9.4%/yr | 4.2 | 0% | 9,220 in 2030+11%/yr |
| North Carolina | 76 | 3,911+8.1%/yr | +8.1%/yr | 3.3 | 0% | 6,900 in 2030+9.9%/yr |
| Tennessee | 60 | 3,741+3.6%/yr | +3.6%/yr | 4.4 | 0% | 6,340 in 2030+9.2%/yr |
| Georgia | 65 | 3,401+5%/yr | +5%/yr | 3.3 | 0% | 7,490 in 2030+14%/yr |
| South Carolina | 41 | 3,270+9.7%/yr | +9.7%/yr | 4.1 | 0% | 6,810 in 2030+13%/yr |
| Alabama | 36 | 2,013+2.1%/yr | +2.1%/yr | 3.7 | 0% | 2,930 in 2030+6.5%/yr |
| Oklahoma | 23 | 1,684+4.1%/yr | +4.1%/yr | 3.0 | 0% | 2,960 in 2030+9.9%/yr |
| Arkansas | 15 | 1,494+3.9%/yr | +3.9%/yr | 3.4 | 0% | 2,460 in 2030+8.7%/yr |
| Kentucky | 30 | 1,317+6.3%/yr | +6.3%/yr | 2.4 | 0% | 2,610 in 2030+12%/yr |
| Louisiana | 27 | 1,317+5.2%/yr | +5.2%/yr | 2.7 | 0% | 2,790 in 2030+13%/yr |
| Mississippi | 10 | 693−0.9%/yr | −0.9%/yr | 1.6 | 0% | 1,160 in 2030+9%/yr |
| West Virginia | 13 | 643+7.7%/yr | +7.7%/yr | 2.6 | 0% | 1,120 in 2030+9.8%/yr |
| District of Columbia | 8 | 503+10%/yr | +10%/yr | 7.1 | 0% | 1,040 in 2030+13%/yr |
| Delaware | 7 | 268+0.4%/yr | +0.4%/yr | 1.4 | 0% | 330 in 2030+3.6%/yr |
| 56 |
| 1,696+8.1%/yr |
| +8.1%/yr |
| 1.80.5× |
| 35% |
| 3,080 in 2030+10%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 41% of company spending on these surgeons in 2025, +39 pts on 2024.
In 2025, 6 companies reported engagement with Maryland’s surgeons worth $159K in consulting, speaking, meals and travel tied to these products, about $3,706 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 102 clearances and approvals in the category, 5 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.